A total of 44 women received a combination of ifosfamide (1.5 g/m
2 daily x5) and cisplatin (50 mg/m
2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.
The London Gynaecology Oncology Group (LGOG) comprising the Departments of Medical Oncology